Clinically validated phage-matching platform

What the forecast means

Milestone stage: clinical validation

early controlled and personalized clinical studies reported

Timing window: 2028–2039. An editorial range, not a statistical confidence interval.

Completion criteria: A standardized platform matches patient bacterial isolates to quality-controlled phage treatments and shows a prespecified clinically meaningful benefit in a confirmatory controlled human trial for one resistant infection. Resolve only from inspectable evidence meeting every stated criterion; a plan or extrapolation does not resolve it.

This page describes a forecast, rather than an achieved result. Read the methodology and assumptions.

Built on

• Randomised controlled trialRecorded · 1948requires
• Next-gen sequencingRecorded · 2005enables
• Automated biofoundriesRecorded · 2015scales with
• Engineered-phage patient treatment reportRecorded · 2019influences

Led to

• AI-found antibiotic classesForecast · ~2032influences

Sources & evidence

• Randomized first-in-human trial of inhaled BX004-A phage cocktail 2025

  2025 phase 1 b/2 a randomized first-in-human trial report included nine adults; evidence is early, not broad clinical efficacy or approval.

• Personalized inhaled bacteriophage therapy for multidrug-resistant P. aeruginosa 2025

  Personalized treatment evidence motivates larger trials; it does not establish routine hospital service.

• Engineered bacteriophages for treatment of a patient with disseminated drug-resistant M. abscessus 2019

  Published 2019 compassionate-use case with engineered phages; case evidence does not establish a generally approved therapy.

Astra editorial synthesis; cited researchers retain credit for their results

Record reviewed 2026-10-18